Nonetheless, in humans avoidance of dietary soy or ingestion of DZN supplements by breast cancer patients receiving estrogen targeted therapy is encouraged (90) despite the fact that the RBA of DZN is 0.003% for ERα and 0.05% for Erβ (91). The gene discussed is ESR2; the disease is breast carcinoma.